882796--3/14/2007--BIOCRYST_PHARMACEUTICALS

related topics

{product, candidate, development}

{product, liability, claim}

{stock, price, operating}

{cost, contract, operation}

{stock, price, share}

{provision, law, control}

{cost, operation, labor}

{product, market, service}

{property, intellectual, protect}

{personnel, key, retain}

{system, service, information}

{cost, regulation, environmental}

If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates or continue our research and development programs. If HHS were to eliminate or reduce funding from our contract, this would have a significant negative impact on our anticipated revenues and cash flows and the development of peramivir. Our contract with HHS has special contracting requirements, which create additional risks or reduction or loss of funding. If we fail to establish collaborative relationships to commercialize certain of our drug product candidates or if any partner terminates or fails to perform its obligations under agreements with us, the commercialization of our product candidates could be delayed or terminated. If our contract research organizations do not successfully carry out their duties or if we lose our relationships with contract research organizations, our drug development efforts could be delayed. We have not commercialized any products or technologies and our future revenue generation is uncertain. If our development collaborations with other parties fail, the development of our drug product candidates will be delayed or stopped. Our development of both intravenous and intramuscular dosing of peramivir for avian flu is subject to all disclosed drug development and potential commercialization risks and numerous additional risks. Any potential revenue benefits to us are highly speculative. Because we have limited manufacturing experience, we depend on third-party manufacturers to manufacture our drug product candidates and the materials for our product candidates. If we cannot rely on third-party manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers. If the clinical trials of our drug product candidates fail, our product candidates will not be marketed, and we will not realize product related revenue. If we or our partners do not obtain and maintain governmental approvals for our products under development, we or our partners will not be able to sell these potential products, which would significantly harm our business because we will receive no revenue. If our drug product candidates do not achieve broad market acceptance, our business may never become profitable. We face intense competition, and if we are unable to compete effectively, the demand for our products, if any, may be reduced. If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish. If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our drug product candidates and the expansion of our business will be delayed or stopped. We may be unable to establish sales, marketing and distribution capabilities necessary to successfully commercialize products we may develop. If users of our drug products are not reimbursed for use, future sales of our drug products will decline. The Medicare prescription drug coverage legislation and future legislative or regulatory reform of the healthcare system may affect our ability to sell our products profitably. There is a substantial risk of product liability claims in our business. If we are unable to obtain sufficient insurance, a product liability claim against us could adversely affect our business. If our computer systems fail or our facility incurs damage, our business will suffer. If, because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts. Risks Relating to Our Common Stock Our stock price is likely to be highly volatile and the value of your investment could decline significantly. Because stock ownership is concentrated, you and other investors will have limited influence on stockholder decisions. We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree. We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.

Full 10-K form ▸

882796--3/14/2007--BIOCRYST_PHARMACEUTICALS_INC